Reviews
Antonio Segovia-Zafra, Daniel E. Di Zeo-Sánchez, Carlos López-Gómez, Zeus Pérez-Valdés, Eduardo García-Fuentes, Raúl J. Andrade, M. Isabel Lucena, Marina Villanueva-Paz. Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction[J]. Acta Pharmaceutica Sinica B, 2021, 11(12): 3685-3726

Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction
Antonio Segovia-Zafraa,b, Daniel E. Di Zeo-Sáncheza, Carlos López-Gómezd, Zeus Pérez-Valdésa, Eduardo García-Fuentesd, Raúl J. Andradea,b, M. Isabel Lucenaa,b,c, Marina Villanueva-Paza
a. Unidad de Gestión Clínica de Gastroenterología, Servicio de Farmacología Clínica, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga 29071, Spain;
b. Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid 28029, Spain;
c. Platform ISCIII de Ensayos Clínicos, UICEC-IBIMA, Málaga 29071, Spain;
d. Unidad de Gestión Clínica de Aparato Digestivo, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Málaga 29010, Spain
Abstract:
Idiosyncratic drug-induced liver injury (iDILI) encompasses the unexpected harms that prescription and non-prescription drugs, herbal and dietary supplements can cause to the liver. iDILI remains a major public health problem and a major cause of drug attrition. Given the lack of biomarkers for iDILI prediction, diagnosis and prognosis, searching new models to predict and study mechanisms of iDILI is necessary. One of the major limitations of iDILI preclinical assessment has been the lack of correlation between the markers of hepatotoxicity in animal toxicological studies and clinically significant iDILI. Thus, major advances in the understanding of iDILI susceptibility and pathogenesis have come from the study of well-phenotyped iDILI patients. However, there are many gaps for explaining all the complexity of iDILI susceptibility and mechanisms. Therefore, there is a need to optimize preclinical human in vitro models to reduce the risk of iDILI during drug development. Here, the current experimental models and the future directions in iDILI modelling are thoroughly discussed, focusing on the human cellular models available to study the pathophysiological mechanisms of the disease and the most used in vivo animal iDILI models. We also comment about in silico approaches and the increasing relevance of patient-derived cellular models.
Key words:    Drug-induced liver injury    Preclinical models    Mechanisms    Oxidative stress    Mitochondrial damage    Immune response    Personalized medicine   
Received: 2021-09-22     Revised: 2021-11-07
DOI: 10.1016/j.apsb.2021.11.013
Funds: This work was supported by grants of Instituto de Salud Carlos III cofounded by Fondo Europeo de Desarrollo Regional-FEDER (contract numbers: PI18/01804, PI19-00883, PT20/00127, UMA18-FEDERJA-194, PY18-3364, Spain) and grants of Consejería de Salud de Andalucía cofounded by FEDER (contract number: PEMP-0127-2020, Spain). M.V.P. holds a Sara Borrell (CD21/00198, Spain) research contract from ISCIII and Consejería de Salud de Andalucía. C.L.G. holds a Juan de la Cierva Incorporación (IJCI-2017-31466, Spain) research contract from Ministerio de Ciencia del Gobierno de España. SCReN and CIBERehd are funded by ISCIII (Spain). This publication is based upon work from COST Action “CA17112—Prospective European Drug-Induced Liver Injury Network” supported by COST (European Cooperation in Science and Technology); www.cost.eu. The figures in this review were created with Biorender.com.
Corresponding author: M. Isabel Lucena,E-mail:lucena@uma.es     Email:lucena@uma.es
Author description:
Service
PDF(KB) Free
Print
0
Authors
Antonio Segovia-Zafra
Daniel E. Di Zeo-Sánchez
Carlos López-Gómez
Zeus Pérez-Valdés
Eduardo García-Fuentes
Raúl J. Andrade
M. Isabel Lucena
Marina Villanueva-Paz

References:
[1] Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol 2015; 63: 503-514
[2] Hoofnagle JH, Bjornsson ES. Drug-induced liver injury-types and phenotypes. N Engl J Med 2019; 381: 264-273
[3] Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451-455
[4] de Abajo FJ, Montero D, Madurga M, Garcia Rodriguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58: 71-80
[5] De Valle MB, Av Klinteberg V, Alem N, Olsson R, Bjornsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther 2006; 24: 1187-1195
[6] Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-1425, 25 e1-3;quiz e19-20
[7] Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 2017; 66: 1154-1164
[8] Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-2076
[9] Kuna L, Bozic I, Kizivat T, Bojanic K, Mrso M, Kralj E, et al. Models of drug induced liver injury (DILI)-current issues and future perspectives. Curr Drug Metab 2018; 19: 830-838
[10] Robles-Diaz M, Lucena MI, Kaplowitz N, Stephens C, Medina-Caliz I, Gonzalez-Jimenez A, et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 2014; 147: 109-118 e5
[11] Ashby K, Zhuang W, Gonzalez-Jimenez A, Alvarez-Alvarez I, Lucena MI, Andrade RJ, et al. Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI. J Hepatol 2021; 75: 333-341
[12] Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89: 806-815
[13] European Association for the Study of the Liver. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol 2019; 70: 1222-1261
[14] Lucena MI, Sanabria J, Garcia-Cortes M, Stephens C, Andrade RJ. Drug-induced liver injury in older people. Lancet Gastroenterol Hepatol 2020; 5: 862-874
[15] Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330
[16] Ulrich RG. Idiosyncratic toxicity: a convergence of risk factors. Annu Rev Med 2007; 58: 17-34
[17] Gonzalez-Jimenez A, McEuen K, Chen M, Suzuki A, Robles-Diaz M, Medina-Caliz I, et al. The influence of drug properties and host factors on delayed onset of symptoms in drug-induced liver injury. Liver Int 2019; 39: 401-410
[18] Macias-Rodriguez RU, Inzaugarat ME, Ruiz-Margain A, Nelson LJ, Trautwein C, Cubero FJ. Reclassifying hepatic cell death during liver damage: ferroptosis-a novel form of non-apoptotic cell death?. Int J Mol Sci 2020; 21: 1651
[19] O'Brien PJ, Chan K, Silber PM. Human and animal hepatocytes in vitro with extrapolation in vivo. Chem Biol Interact 2004; 150: 97-114
[20] Hendriks DF, Fredriksson Puigvert L, Messner S, Mortiz W, Ingelman-Sundberg M. Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability. Sci Rep 2016; 6: 35434
[21] Richert L, Liguori MJ, Abadie C, Heyd B, Mantion G, Halkic N, et al. Gene expression in human hepatocytes in suspension after isolation is similar to the liver of origin, is not affected by hepatocyte cold storage and cryopreservation, but is strongly changed after hepatocyte plating. Drug Metab Dispos 2006; 34: 870-879
[22] Vorrink SU, Zhou Y, Ingelman-Sundberg M, Lauschke VM. Prediction of drug-induced hepatotoxicity using long-term stable primary hepatic 3D spheroid cultures in chemically defined conditions. Toxicol Sci 2018; 163: 655-665
[23] Kamalian L, Chadwick AE, Bayliss M, French NS, Monshouwer M, Snoeys J, et al. The utility of HepG2 cells to identify direct mitochondrial dysfunction in the absence of cell death. Toxicol In Vitro 2015; 29: 732-740
[24] Xuan J, Chen S, Ning B, Tolleson WH, Guo L. Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity. Chem Biol Interact 2016; 255: 63-73
[25] Wink S, Hiemstra SW, Huppelschoten S, Klip JE, van de Water B. Dynamic imaging of adaptive stress response pathway activation for prediction of drug induced liver injury. Arch Toxicol 2018; 92: 1797-1814
[26] Antherieu S, Chesne C, Li R, Guguen-Guillouzo C, Guillouzo A. Optimization of the HepaRG cell model for drug metabolism and toxicity studies. Toxicol In Vitro 2012; 26: 1278-1285
[27] Tolosa L, Gomez-Lechon MJ, Jimenez N, Hervas D, Jover R, Donato MT. Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis. Toxicol Appl Pharmacol 2016; 302: 1-9
[28] Choi S, Sainz B Jr, Corcoran P, Uprichard S, Jeong H. Characterization of increased drug metabolism activity in dimethyl sulfoxide (DMSO)-treated Huh7 hepatoma cells. Xenobiotica 2009; 39: 205-217
[29] Chu CC, Pan KL, Yao HT, Hsu JT. Development of a whole-cell screening system for evaluation of the human CYP1A2-mediated metabolism. Biotechnol Bioeng 2011; 108: 2932-2940
[30] Apostolova N, Gomez-Sucerquia LJ, Gortat A, Blas-Garcia A, Esplugues JV. Compromising mitochondrial function with the antiretroviral drug efavirenz induces cell survival-promoting autophagy. Hepatology 2011; 54: 1009-1019
[31] Apostolova N, Gomez-Sucerquia LJ, Alegre F, Funes HA, Victor VM, Barrachina MD, et al. ER stress in human hepatic cells treated with Efavirenz: mitochondria again. J Hepatol 2013; 59: 780-789
[32] Polo M, Alegre F, Funes HA, Blas-Garcia A, Victor VM, Esplugues JV, et al. Mitochondrial (dys)function-a factor underlying the variability of efavirenz-induced hepatotoxicity?. Br J Pharmacol 2015; 172: 1713-1727
[33] Thompson RA, Isin EM, Li Y, Weidolf L, Page K, Wilson I, et al. In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Chem Res Toxicol 2012; 25: 1616-1632
[34] Gustafsson F, Foster AJ, Sarda S, Bridgland-Taylor MH, Kenna JG. A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. Toxicol Sci 2014; 137: 189-211
[35] Yildirimman R, Brolen G, Vilardell M, Eriksson G, Synnergren J, Gmuender H, et al. Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. Toxicol Sci 2011; 124: 278-290
[36] Kim DE, Jang MJ, Kim YR, Lee JY, Cho EB, Kim E, et al. Prediction of drug-induced immune-mediated hepatotoxicity using hepatocyte-like cells derived from human embryonic stem cells. Toxicology 2017; 387: 1-9
[37] Cipriano M, Pinheiro PF, Sequeira CO, Rodrigues JS, Oliveira NG, Antunes AMM, et al. Nevirapine biotransformation insights: an integrated in vitro approach unveils the biocompetence and glutathiolomic profile of a human hepatocyte-like cell 3D model. Int J Mol Sci 2020; 21: 3998
[38] Choudhury Y, Toh YC, Xing J, Qu Y, Poh J, Li H, et al. Patient-specific hepatocyte-like cells derived from induced pluripotent stem cells model pazopanib-mediated hepatotoxicity. Sci Rep 2017; 7: 41238
[39] Imagawa K, Takayama K, Isoyama S, Tanikawa K, Shinkai M, Harada K, et al. Generation of a bile salt export pump deficiency model using patient-specific induced pluripotent stem cell-derived hepatocyte-like cells. Sci Rep 2017; 7: 41806
[40] Deguchi S, Yamashita T, Igai K, Harada K, Toba Y, Hirata K, et al. Modeling of hepatic drug metabolism and responses in CYP2C19 poor metabolizer using genetically manipulated human iPS cells. Drug Metab Dispos 2019; 47: 632-638
[41] Novik E, Maguire TJ, Chao P, Cheng KC, Yarmush ML. A microfluidic hepatic coculture platform for cell-based drug metabolism studies. Biochem Pharmacol 2010; 79: 1036-1044
[42] Nguyen TV, Ukairo O, Khetani SR, McVay M, Kanchagar C, Seghezzi W, et al. Establishment of a hepatocyte-kupffer cell coculture model for assessment of proinflammatory cytokine effects on metabolizing enzymes and drug transporters. Drug Metab Dispos 2015; 43: 774-785
[43] Baze A, Parmentier C, Hendriks DFG, Hurrell T, Heyd B, Bachellier P, et al. Three-dimensional spheroid primary human hepatocytes in monoculture and coculture with nonparenchymal cells. Tissue Eng Part C Methods 2018; 24: 534-545
[44] Khetani SR, Bhatia SN. Microscale culture of human liver cells for drug development. Nat Biotechnol 2008; 26: 120-126
[45] March S, Ramanan V, Trehan K, Ng S, Galstian A, Gural N, et al. Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens. Nat Protoc 2015; 10: 2027-2053
[46] Chan TS, Yu H, Moore A, Khetani SR, Tweedie D. Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac. Drug Metab Dispos 2019; 47: 58-66
[47] Elferink MG, Olinga P, van Leeuwen EM, Bauerschmidt S, Polman J, Schoonen WG, et al. Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol 2011; 253: 57-69
[48] Hadi M, Westra IM, Starokozhko V, Dragovic S, Merema MT, Groothuis GM. Human precision-cut liver slices as an ex vivo model to study idiosyncratic drug-induced liver injury. Chem Res Toxicol 2013; 26: 710-720
[49] Ma L, Wu Y, Li Y, Aazmi A, Zhou H, Zhang B, et al. Current advances on 3D-bioprinted liver tissue models. Adv Healthc Mater 2020; 9: e2001517
[50] Serras AS, Rodrigues JS, Cipriano M, Rodrigues AV, Oliveira NG, Miranda JP. A critical perspective on 3D liver models for drug metabolism and toxicology studies. Front Cell Dev Biol 2021; 9: 626805
[51] Baudoin R, Prot JM, Nicolas G, Brocheton J, Brochot C, Legallais C, et al. Evaluation of seven drug metabolisms and clearances by cryopreserved human primary hepatocytes cultivated in microfluidic biochips. Xenobiotica 2013; 43: 140-152
[52] Choucha Snouber L, Bunescu A, Naudot M, Legallais C, Brochot C, Dumas ME, et al. Metabolomics-on-a-chip of hepatotoxicity induced by anticancer drug flutamide and Its active metabolite hydroxyflutamide using HepG2/C3a microfluidic biochips. Toxicol Sci 2013; 132: 8-20
[53] Rubiano A, Indapurkar A, Yokosawa R, Miedzik A, Rosenzweig B, Arefin A, et al. Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation. Clin Transl Sci 2021; 14: 1049-1061
[54] Wagner I, Materne EM, Brincker S, Sussbier U, Fradrich C, Busek M, et al. A dynamic multi-organ-chip for long-term cultivation and substance testing proven by 3D human liver and skin tissue co-culture. Lab Chip 2013; 13: 3538-3547
[55] Bricks T, Paullier P, Legendre A, Fleury MJ, Zeller P, Merlier F, et al. Development of a new microfluidic platform integrating co-cultures of intestinal and liver cell lines. Toxicol In Vitro 2014; 28: 885-895
[56] Oleaga C, Bernabini C, Smith AS, Srinivasan B, Jackson M, McLamb W, et al. Multi-organ toxicity demonstration in a functional human in vitro system composed of four organs. Sci Rep 2016; 6: 20030
[57] Zeilinger K, Freyer N, Damm G, Seehofer D, Knospel F. Cell sources for in vitro human liver cell culture models. Exp Biol Med (Maywood) 2016; 241: 1684-1698
[58] Lin C, Ballinger KR, Khetani SR. The application of engineered liver tissues for novel drug discovery. Expert Opin Drug Discov 2015; 10: 519-540
[59] Sison-Young RL, Mitsa D, Jenkins RE, Mottram D, Alexandre E, Richert L, et al. Comparative proteomic characterization of 4 human liver-derived single cell culture models reveals significant variation in the capacity for drug disposition, bioactivation, and detoxication. Toxicol Sci 2015; 147: 412-424
[60] Sison-Young RL, Lauschke VM, Johann E, Alexandre E, Antherieu S, Aerts H, et al. A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity. Arch Toxicol 2017; 91: 1385-1400
[61] den Braver-Sewradj SP, den Braver MW, Vermeulen NP, Commandeur JN, Richert L, Vos JC. Inter-donor variability of phase I/phase II metabolism of three reference drugs in cryopreserved primary human hepatocytes in suspension and monolayer. Toxicol In Vitro 2016; 33: 71-79
[62] Inoue C, Yamamoto H, Nakamura T, Ichihara A, Okamoto H. Nicotinamide prolongs survival of primary cultured hepatocytes without involving loss of hepatocyte-specific functions. J Biol Chem 1989; 264: 4747-4750
[63] Kost DP, Michalopoulos GK. Effect of 2% dimethyl sulfoxide on the mitogenic properties of epidermal growth factor and hepatocyte growth factor in primary hepatocyte culture. J Cell Physiol 1991; 147: 274-280
[64] Tolosa L, Gomez-Lechon MJ, Lopez S, Guzman C, Castell JV, Donato MT, et al. Human upcyte hepatocytes: characterization of the hepatic phenotype and evaluation for acute and long-term hepatotoxicity routine testing. Toxicol Sci 2016; 152: 214-229
[65] Tolosa L, Jimenez N, Pelecha M, Castell JV, Gomez-Lechon MJ, Donato MT. Long-term and mechanistic evaluation of drug-induced liver injury in Upcyte human hepatocytes. Arch Toxicol 2019; 93: 519-532
[66] Schulz C, Kammerer S, Kupper JH. NADPH-cytochrome P450 reductase expression and enzymatic activity in primary-like human hepatocytes and HepG2 cells for in vitro biotransformation studies. Clin Hemorheol Microcirc 2019; 73: 249-260
[67] Schaefer M, Morinaga G, Matsui A, Schanzle G, Bischoff D, Sussmuth RD. Quantitative expression of hepatobiliary transporters and functional uptake of substrates in hepatic two-dimensional sandwich cultures: a comparative evaluation of upcyte and primary human hepatocytes. Drug Metab Dispos 2018; 46: 166-177
[68] Guo L, Dial S, Shi L, Branham W, Liu J, Fang JL, et al. Similarities and differences in the expression of drug-metabolizing enzymes between human hepatic cell lines and primary human hepatocytes. Drug Metab Dispos 2011; 39: 528-538
[69] Gerets HH, Tilmant K, Gerin B, Chanteux H, Depelchin BO, Dhalluin S, et al. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol 2012; 28: 69-87
[70] Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 1979; 282: 615-616
[71] Costantini S, Di Bernardo G, Cammarota M, Castello G, Colonna G. Gene expression signature of human HepG2 cell line. Gene 2013; 518: 335-345
[72] Doostdar H, Duthie SJ, Burke MD, Melvin WT, Grant MH. The influence of culture medium composition on drug metabolising enzyme activities of the human liver derived Hep G2 cell line. FEBS Lett 1988; 241: 15-18
[73] Tyakht AV, Ilina EN, Alexeev DG, Ischenko DS, Gorbachev AY, Semashko TA, et al. RNA-Seq gene expression profiling of HepG2 cells: the influence of experimental factors and comparison with liver tissue. BMC Genomics 2014; 15: 1108
[74] Tolosa L, Jimenez N, Perez G, Castell JV, Gomez-Lechon MJ, Donato MT. Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury. Arch Toxicol 2018; 92: 383-399
[75] Tolosa L, Gomez-Lechon MJ, Perez-Cataldo G, Castell JV, Donato MT. HepG2 cells simultaneously expressing five P450 enzymes for the screening of hepatotoxicity: identification of bioactivable drugs and the potential mechanism of toxicity involved. Arch Toxicol 2013; 87: 1115-1127
[76] Donato MT, Jover R, Gomez-Lechon MJ. Hepatic cell lines for drug hepatotoxicity testing: limitations and strategies to upgrade their metabolic competence by gene engineering. Curr Drug Metab 2013; 14: 946-968
[77] Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 1982; 42: 3858-3863
[78] Louisa M, Suyatna FD, Wanandi SI, Asih PB, Syafruddin D. Differential expression of several drug transporter genes in HepG2 and Huh-7 cell lines. Adv Biomed Res 2016; 5: 104
[79] Sivertsson L, Edebert I, Palmertz MP, Ingelman-Sundberg M, Neve EP. Induced CYP3A4 expression in confluent Huh7 hepatoma cells as a result of decreased cell proliferation and subsequent pregnane X receptor activation. Mol Pharmacol 2013; 83: 659-670
[80] Khamphaya T, Chukijrungroat N, Saengsirisuwan V, Mitchell-Richards KA, Robert ME, Mennone A, et al. Nonalcoholic fatty liver disease impairs expression of the type II inositol 1,4,5-trisphosphate receptor. Hepatology 2018; 67: 560-574
[81] Mace K, Aguilar F, Wang JS, Vautravers P, Gomez-Lechon M, Gonzalez FJ, et al. Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis 1997; 18: 1291-1297
[82] Glaise D, Ilyin GP, Loyer P, Cariou S, Bilodeau M, Lucas J, et al. Cell cycle gene regulation in reversibly differentiated new human hepatoma cell lines. Cell Growth Differ 1998; 9: 165-176
[83] Mills JB, Rose KA, Sadagopan N, Sahi J, de Morais SM. Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J Pharmacol Exp Ther 2004; 309: 303-309
[84] Scott CW, Peters MF, Dragan YP. Human induced pluripotent stem cells and their use in drug discovery for toxicity testing. Toxicol Lett 2013; 219: 49-58
[85] Rambhatla L, Chiu CP, Kundu P, Peng Y, Carpenter MK. Generation of hepatocyte-like cells from human embryonic stem cells. Cell Transplant 2003; 12: 1-11
[86] Lavon N, Yanuka O, Benvenisty N. Differentiation and isolation of hepatic-like cells from human embryonic stem cells. Differentiation 2004; 72: 230-238
[87] Schwartz RE, Linehan JL, Painschab MS, Hu WS, Verfaillie CM, Kaufman DS. Defined conditions for development of functional hepatic cells from human embryonic stem cells. Stem Cells Dev 2005; 14: 643-655
[88] Takayama K, Inamura M, Kawabata K, Katayama K, Higuchi M, Tashiro K, et al. Efficient generation of functional hepatocytes from human embryonic stem cells and induced pluripotent stem cells by HNF4alpha transduction. Mol Ther 2012; 20: 127-137
[89] Li Z, Wu J, Wang L, Han W, Yu J, Liu X, et al. Generation of qualified clinical-grade functional hepatocytes from human embryonic stem cells in chemically defined conditions. Cell Death Dis 2019; 10: 763
[90] Xia Y, Carpentier A, Cheng X, Block PD, Zhao Y, Zhang Z, et al. Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions. J Hepatol 2017; 66: 494-503
[91] Lee HJ, Jung J, Cho KJ, Lee CK, Hwang SG, Kim GJ. Comparison of in vitro hepatogenic differentiation potential between various placenta-derived stem cells and other adult stem cells as an alternative source of functional hepatocytes. Differentiation 2012; 84: 223-231
[92] Cipriano M, Correia JC, Camoes SP, Oliveira NG, Cruz P, Cruz H, et al. The role of epigenetic modifiers in extended cultures of functional hepatocyte-like cells derived from human neonatal mesenchymal stem cells. Arch Toxicol 2017; 91: 2469-2489
[93] Moon JH, Heo JS, Kim JS, Jun EK, Lee JH, Kim A, et al. Reprogramming fibroblasts into induced pluripotent stem cells with Bmi1. Cell Res 2011; 21: 1305-1315
[94] Si-Tayeb K, Noto FK, Nagaoka M, Li J, Battle MA, Duris C, et al. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology 2010; 51: 297-305
[95] Takata A, Otsuka M, Kogiso T, Kojima K, Yoshikawa T, Tateishi R, et al. Direct differentiation of hepatic cells from human induced pluripotent stem cells using a limited number of cytokines. Hepatol Int 2011; 5: 890-898
[96] Nakamura N, Saeki K, Mitsumoto M, Matsuyama S, Nishio M, Saeki K, et al. Feeder-free and serum-free production of hepatocytes, cholangiocytes, and their proliferating progenitors from human pluripotent stem cells: application to liver-specific functional and cytotoxic assays. Cell Reprogram 2012; 14: 171-185
[97] Schwartz RE, Fleming HE, Khetani SR, Bhatia SN. Pluripotent stem cell-derived hepatocyte-like cells. Biotechnol Adv 2014; 32: 504-513
[98] Li S, Guo J, Ying Z, Chen S, Yang L, Chen K, et al. Valproic acid-induced hepatotoxicity in Alpers syndrome is associated with mitochondrial permeability transition pore opening-dependent apoptotic sensitivity in an induced pluripotent stem cell model. Hepatology 2015; 61: 1730-1739
[99] Pfeiffer E, Kegel V, Zeilinger K, Hengstler JG, Nussler AK, Seehofer D, et al. Featured Article: Isolation, characterization, and cultivation of human hepatocytes and non-parenchymal liver cells. Exp Biol Med (Maywood) 2015; 240: 645-656
[100] Granitzny A, Knebel J, Muller M, Braun A, Steinberg P, Dasenbrock C, et al. Evaluation of a human in vitro hepatocyte-NPC co-culture model for the prediction of idiosyncratic drug-induced liver injury: a pilot study. Toxicol Rep 2017; 4: 89-103
[101] Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 2002; 99: 15655-15660
[102] Le Vee M, Noel G, Jouan E, Stieger B, Fardel O. Polarized expression of drug transporters in differentiated human hepatoma HepaRG cells. Toxicol In Vitro 2013; 27: 1979-1986
[103] Josse R, Aninat C, Glaise D, Dumont J, Fessard V, Morel F, et al. Long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies. Drug Metab Dispos 2008; 36: 1111-1118
[104] Antherieu S, Rogue A, Fromenty B, Guillouzo A, Robin MA. Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells. Hepatology 2011; 53: 1895-1905
[105] Jenne CN, Kubes P. Immune surveillance by the liver. Nat Immunol 2013; 14: 996-1006
[106] Olsen AL, Bloomer SA, Chan EP, Gaca MD, Georges PC, Sackey B, et al. Hepatic stellate cells require a stiff environment for myofibroblastic differentiation. Am J Physiol Gastrointest Liver Physiol 2011; 301: G110-G118
[107] Ware BR, Durham MJ, Monckton CP, Khetani SR. A cell culture platform to maintain long-term phenotype of primary human hepatocytes and endothelial cells. Cell Mol Gastroenterol Hepatol 2018; 5: 187-207
[108] Khetani SR, Berger DR, Ballinger KR, Davidson MD, Lin C, Ware BR. Microengineered liver tissues for drug testing. J Lab Autom 2015; 20: 216-250
[109] Proctor WR, Foster AJ, Vogt J, Summers C, Middleton B, Pilling MA, et al. Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury. Arch Toxicol 2017; 91: 2849-2863
[110] Khetani SR, Kanchagar C, Ukairo O, Krzyzewski S, Moore A, Shi J, et al. Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans. Toxicol Sci 2013; 132: 107-117
[111] Lin C, Shi J, Moore A, Khetani SR. Prediction of drug clearance and drug-drug interactions in microscale cultures of human hepatocytes. Drug Metab Dispos 2016; 44: 127-136
[112] Graaf IA, Groothuis GM, Olinga P. Precision-cut tissue slices as a tool to predict metabolism of novel drugs. Expert Opin Drug Metab Toxicol 2007; 3: 879-898
[113] Vickers AE, Bentley P, Fisher RL. Consequences of mitochondrial injury induced by pharmaceutical fatty acid oxidation inhibitors is characterized in human and rat liver slices. Toxicol In Vitro 2006; 20: 1173-1182
[114] Edwards RJ, Price RJ, Watts PS, Renwick AB, Tredger JM, Boobis AR, et al. Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 2003; 31: 282-288
[115] Starokozhko V, Vatakuti S, Schievink B, Merema MT, Asplund A, Synnergren J, et al. Maintenance of drug metabolism and transport functions in human precision-cut liver slices during prolonged incubation for 5 days. Arch Toxicol 2017; 91: 2079-2092
[116] Palma E, Doornebal EJ, Chokshi S. Precision-cut liver slices: a versatile tool to advance liver research. Hepatol Int 2019; 13: 51-57
[117] Gomez-Lechon MJ, Tolosa L, Conde I, Donato MT. Competency of different cell models to predict human hepatotoxic drugs. Expert Opin Drug Metab Toxicol 2014; 10: 1553-1568
[118] De Bruyn T, Chatterjee S, Fattah S, Keemink J, Nicolai J, Augustijns P, et al. Sandwich-cultured hepatocytes: utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity. Expert Opin Drug Metab Toxicol 2013; 9: 589-616
[119] Hewitt NJ, Lechon MJ, Houston JB, Hallifax D, Brown HS, Maurel P, et al. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 2007; 39: 159-234
[120] Berger DR, Ware BR, Davidson MD, Allsup SR, Khetani SR. Enhancing the functional maturity of induced pluripotent stem cell-derived human hepatocytes by controlled presentation of cell-cell interactions in vitro. Hepatology 2015; 61: 1370-1381
[121] Takahashi Y, Hori Y, Yamamoto T, Urashima T, Ohara Y, Tanaka H. 3D spheroid cultures improve the metabolic gene expression profiles of HepaRG cells. Biosci Rep 2015; 35: e00208
[122] Bell CC, Hendriks DF, Moro SM, Ellis E, Walsh J, Renblom A, et al. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Sci Rep 2016; 6: 25187
[123] Sirenko O, Hancock MK, Hesley J, Hong D, Cohen A, Gentry J, et al. Phenotypic characterization of toxic compound effects on liver spheroids derived from iPSC using confocal imaging and three-dimensional image analysis. Assay Drug Dev Technol 2016; 14: 381-394
[124] Andria B, Bracco A, Cirino G, Chamuleau RA. Liver cell culture devices. Cell Med 2010; 1: 55-70
[125] Kostadinova R, Boess F, Applegate D, Suter L, Weiser T, Singer T, et al. A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. Toxicol Appl Pharmacol 2013; 268: 1-16
[126] Ohkura T, Ohta K, Nagao T, Kusumoto K, Koeda A, Ueda T, et al. Evaluation of human hepatocytes cultured by three-dimensional spheroid systems for drug metabolism. Drug Metab Pharmacokinet 2014; 29: 373-378
[127] Takayama K, Kawabata K, Nagamoto Y, Kishimoto K, Tashiro K, Sakurai F, et al. 3D spheroid culture of hESC/hiPSC-derived hepatocyte-like cells for drug toxicity testing. Biomaterials 2013; 34: 1781-1789
[128] Leite SB, Roosens T, El Taghdouini A, Mannaerts I, Smout AJ, Najimi M, et al. Novel human hepatic organoid model enables testing of drug-induced liver fibrosis in vitro. Biomaterials 2016; 78: 1-10
[129] Broutier L, Andersson-Rolf A, Hindley CJ, Boj SF, Clevers H, Koo BK, et al. Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. Nat Protoc 2016; 11: 1724-1743
[130] Nguyen DG, Funk J, Robbins JB, Crogan-Grundy C, Presnell SC, Singer T, et al. Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicity in vitro. PLoS One 2016; 11: e0158674
[131] Ide I, Nagao E, Kajiyama S, Mizoguchi N. A novel evaluation method for determining drug-induced hepatotoxicity using 3D bio-printed human liver tissue. Toxicol Mech Methods 2020; 30: 189-196
[132] Wang JZ, Xiong NY, Zhao LZ, Hu JT, Kong DC, Yuan JY. Review fantastic medical implications of 3D-printing in liver surgeries, liver regeneration, liver transplantation and drug hepatotoxicity testing: a review. Int J Surg 2018; 56: 1-6
[133] Norona LM, Nguyen DG, Gerber DA, Presnell SC, LeCluyse EL. Editor's highlight: Modeling compound-induced fibrogenesis in vitro using three-dimensional bioprinted human liver tissues. Toxicol Sci 2016; 154: 354-367
[134] Schmidt K, Berg J, Roehrs V, Kurreck J, Al-Zeer MA. 3D-bioprinted HepaRG cultures as a model for testing long term aflatoxin B1 toxicity in vitro. Toxicol Rep 2020; 7: 1578-1587
[135] Peck RW, Hinojosa CD, Hamilton GA. Organs-on-chips in clinical pharmacology: putting the patient into the center of treatment selection and drug development. Clin Pharmacol Ther 2020; 107: 181-185
[136] Viravaidya K, Sin A, Shuler ML. Development of a microscale cell culture analog to probe naphthalene toxicity. Biotechnol Prog 2004; 20: 316-323
[137] Regev A. Drug-induced liver injury and drug development: industry perspective. Semin Liver Dis 2014; 34: 227-239
[138] Watkins PB. Drug safety sciences and the bottleneck in drug development. Clin Pharmacol Ther 2011; 89: 788-790
[139] Gerussi A, Natalini A, Antonangeli F, Mancuso C, Agostinetto E, Barisani D, et al. Immune-mediated drug-induced liver injury: immunogenetics and experimental models. Int J Mol Sci 2021; 22: 4557
[140] Walker PA, Ryder S, Lavado A, Dilworth C, Riley RJ. The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development. Arch Toxicol 2020; 94: 2559-2585
[141] Weaver RJ, Blomme EA, Chadwick AE, Copple IM, Gerets HHJ, Goldring CE, et al. Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. Nat Rev Drug Discov 2020; 19: 131-148
[142] European Medicines Agency. Reflection paper on non-clinical evaluation of drug-induced liver injury (DILI). Published [19/07/2010]. Updated [19/07/2010]. Accessed [04/11/2021]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-non-clinical-evaluation-drug-induced-liver-injury-dili_en.pdf
[143] US Food and Drug Administration. Guidance for industry: drug-induced liver injury: premarketing clinical evaluation. Published [01/07/2009]. Updated [17/10/2019]. Accessed [04/11/2021]. Available from: https://www.fda.gov/media/116737/download
[144] Weaver RJ, Betts C, Blomme EAG, Gerets HHJ, Gjervig Jensen K, Hewitt PG, et al. Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury. Expert Opin Drug Metab Toxicol 2017; 13: 767-782
[145] McGill MR. The problem with predictive values: are we using the right metrics for preclinical prediction of drug hepatotoxicity?. Toxicol Sci 2018; 165: 3-4
[146] Ingelman-Sundberg M, Lauschke VM. Current statistical metrics are pragmatic measures to compare the predictive quality of preclinical assays. Toxicol Sci 2018; 165: 4-5
[147] Gilbert DF, Friedrich O. Cell viability assays: methods and protocols. Methods in molecular biology. New York: Humana Press, 2017
[148] Atienzar FA, Blomme EA, Chen M, Hewitt P, Kenna JG, Labbe G, et al. Key challenges and opportunities associated with the use of in vitro models to detect human DILI: integrated risk assessment and mitigation plans. Biomed Res Int 2016; 2016: 9737920
[149] Xu JJ, Henstock PV, Dunn MC, Smith AR, Chabot JR, de Graaf D. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 2008; 105: 97-105
[150] Thompson RA, Isin EM, Ogese MO, Mettetal JT, Williams DP. Reactive metabolites: current and emerging risk and hazard assessments. Chem Res Toxicol 2016; 29: 505-533
[151] Iorga A, Dara L, Kaplowitz N. Drug-induced liver injury: cascade of events leading to cell death, apoptosis or necrosis. Int J Mol Sci 2017; 18: 1018
[152] Nakayama S, Atsumi R, Takakusa H, Kobayashi Y, Kurihara A, Nagai Y, et al. A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab Dispos 2009; 37: 1970-1977
[153] Norman BH. Drug induced liver injury (DILI). Mechanisms and medicinal chemistry avoidance/mitigation strategies. J Med Chem 2020; 63: 11397-11419
[154] Ramachandran A, Jaeschke H. Oxidative stress and acute hepatic injury. Curr Opin Toxicol 2018; 7: 17-21
[155] Brink A, Pahler A, Funk C, Schuler F, Schadt S. Minimizing the risk of chemically reactive metabolite formation of new drug candidates: implications for preclinical drug design. Drug Discov Today 2017; 22: 751-756
[156] Chen S, Zhang Z, Qing T, Ren Z, Yu D, Couch L, et al. Activation of the Nrf2 signaling pathway in usnic acid-induced toxicity in HepG2 cells. Arch Toxicol 2017; 91: 1293-1307
[157] Antherieu S, Bachour-El Azzi P, Dumont J, Abdel-Razzak Z, Guguen-Guillouzo C, Fromenty B, et al. Oxidative stress plays a major role in chlorpromazine-induced cholestasis in human HepaRG cells. Hepatology 2013; 57: 1518-1529
[158] Han D, Dara L, Win S, Than TA, Yuan L, Abbasi SQ, et al. Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria. Trends Pharmacol Sci 2013; 34: 243-253
[159] Pessayre D, Fromenty B, Berson A, Robin MA, Letteron P, Moreau R, et al. Central role of mitochondria in drug-induced liver injury. Drug Metab Rev 2012; 44: 34-87
[160] Boelsterli UA, Lim PL. Mitochondrial abnormalities-a link to idiosyncratic drug hepatotoxicity?. Toxicol Appl Pharmacol 2007; 220: 92-107
[161] Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol 2008; 22: 335-353
[162] Begriche K, Massart J, Robin MA, Borgne-Sanchez A, Fromenty B. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol 2011; 54: 773-794
[163] Pessayre D, Mansouri A, Berson A, Fromenty B. Mitochondrial involvement in drug-induced liver injury. Handb Exp Pharmacol 2010: 311-365
[164] Porceddu M, Buron N, Roussel C, Labbe G, Fromenty B, Borgne-Sanchez A. Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria. Toxicol Sci 2012; 129: 332-345
[165] Porceddu M, Buron N, Rustin P, Fromenty B, Borgne-Sanchez A. In vitro assessment of mitochondrial toxicity to predict drug-induced liver injury. In: Chen M, Will Y, Editors. Drug-induced liver toxicity. New York: Springer New York; 2018. p. 283-300
[166] Marroquin LD, Hynes J, Dykens JA, Jamieson JD, Will Y. Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol Sci 2007; 97: 539-547
[167] Rana P, Aleo MD, Gosink M, Will Y. Evaluation of in vitro mitochondrial toxicity assays and physicochemical properties for prediction of organ toxicity using 228 pharmaceutical drugs. Chem Res Toxicol 2019; 32: 156-167
[168] Nadanaciva S, Rana P, Beeson GC, Chen D, Ferrick DA, Beeson CC, et al. Assessment of drug-induced mitochondrial dysfunction via altered cellular respiration and acidification measured in a 96-well platform. J Bioenerg Biomembr 2012; 44: 421-437
[169] Eakins J, Bauch C, Woodhouse H, Park B, Bevan S, Dilworth C, et al. A combined in vitro approach to improve the prediction of mitochondrial toxicants. Toxicol In Vitro 2016; 34: 161-170
[170] Tirmenstein MA, Hu CX, Gales TL, Maleeff BE, Narayanan PK, Kurali E, et al. Effects of troglitazone on HepG2 viability and mitochondrial function. Toxicol Sci 2002; 69: 131-138
[171] Dykens JA, Jamieson JD, Marroquin LD, Nadanaciva S, Xu JJ, Dunn MC, et al. In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol Sci 2008; 103: 335-345
[172] Hynes J, Nadanaciva S, Swiss R, Carey C, Kirwan S, Will Y. A high-throughput dual parameter assay for assessing drug-induced mitochondrial dysfunction provides additional predictivity over two established mitochondrial toxicity assays. Toxicol In Vitro 2013; 27: 560-569
[173] Moran M, Delmiro A, Blazquez A, Ugalde C, Arenas J, Martin MA. Bulk autophagy, but not mitophagy, is increased in cellular model of mitochondrial disease. Biochim Biophys Acta 2014; 1842: 1059-1070
[174] Cotan D, Cordero MD, Garrido-Maraver J, Oropesa-Avila M, Rodriguez-Hernandez A, Gomez Izquierdo L, et al. Secondary coenzyme Q10 deficiency triggers mitochondria degradation by mitophagy in MELAS fibroblasts. FASEB J 2011; 25: 2669-2687
[175] Moles A, Torres S, Baulies A, Garcia-Ruiz C, Fernandez-Checa JC. Mitochondrial-lysosomal axis in acetaminophen hepatotoxicity. Front Pharmacol 2018; 9: 453
[176] Jung SH, Lee W, Park SH, Lee KY, Choi YJ, Choi S, et al. Diclofenac impairs autophagic flux via oxidative stress and lysosomal dysfunction: implications for hepatotoxicity. Redox Biol 2020; 37: 101751
[177] Torres S, Baulies A, Insausti-Urkia N, Alarcon-Vila C, Fucho R, Solsona-Vilarrasa E, et al. Endoplasmic reticulum stress-induced upregulation of STARD1 promotes acetaminophen-induced acute liver failure. Gastroenterology 2019; 157: 552-568
[178] Sano R, Reed JC. ER stress-induced cell death mechanisms. Biochim Biophys Acta 2013; 1833: 3460-3470
[179] Liu J, Ren F, Cheng Q, Bai L, Shen X, Gao F, et al. Endoplasmic reticulum stress modulates liver inflammatory immune response in the pathogenesis of liver ischemia and reperfusion injury. Transplantation 2012; 94: 211-217
[180] Ren Z, Chen S, Zhang J, Doshi U, Li AP, Guo L. Endoplasmic reticulum stress induction and ERK1/2 activation contribute to nefazodone-induced toxicity in hepatic cells. Toxicol Sci 2016; 154: 368-380
[181] Chen S, Zhang Z, Wu Y, Shi Q, Yan H, Mei N, et al. Endoplasmic reticulum stress and store-operated calcium entry contribute to usnic acid-induced toxicity in hepatic cells. Toxicol Sci 2015; 146: 116-126
[182] Mosedale M, Watkins PB. Drug-induced liver injury: advances in mechanistic understanding that will inform risk management. Clin Pharmacol Ther 2017; 101: 469-480
[183] Yang K, Kock K, Sedykh A, Tropsha A, Brouwer KL. An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters. J Pharm Sci 2013; 102: 3037-3057
[184] Garzel B, Yang H, Zhang L, Huang SM, Polli JE, Wang H. The role of bile salt export pump gene repression in drug-induced cholestatic liver toxicity. Drug Metab Dispos 2014; 42: 318-322
[185] Ulzurrun E, Stephens C, Crespo E, Ruiz-Cabello F, Ruiz-Nunez J, Saenz-Lopez P, et al. Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drug-induced liver injury. Liver Int 2013; 33: 1378-1385
[186] Stieger B, Mahdi ZM. Model systems for studying the role of canalicular efflux transporters in drug-induced cholestatic liver disease. J Pharm Sci 2017; 106: 2295-2301
[187] Kock K, Ferslew BC, Netterberg I, Yang K, Urban TJ, Swaan PW, et al. Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4. Drug Metab Dispos 2014; 42: 665-674
[188] Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, et al. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci 2010; 118: 485-500
[189] Jemnitz K, Veres Z, Vereczkey L. Contribution of high basolateral bile salt efflux to the lack of hepatotoxicity in rat in response to drugs inducing cholestasis in human. Toxicol Sci 2010; 115: 80-88
[190] Ellis EC, Nilsson LM. The use of human hepatocytes to investigate bile acid synthesis. Methods Mol Biol 2010; 640: 417-430
[191] Yang K, Guo C, Woodhead JL, St Claire RL, 3rd, Watkins PB, Siler SQ, et al. Sandwich-cultured hepatocytes as a tool to study drug disposition and drug-induced liver injury. J Pharm Sci 2016; 105: 443-459
[192] Guo L, Zhang L, Sun Y, Muskhelishvili L, Blann E, Dial S, et al. Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells. Mol Divers 2006; 10: 349-360
[193] Pedersen JM, Matsson P, Bergstrom CAS, Hoogstraate J, Noren A, LeCluyse EL, et al. Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci 2013; 136: 328-343
[194] Oorts M, Baze A, Bachellier P, Heyd B, Zacharias T, Annaert P, et al. Drug-induced cholestasis risk assessment in sandwich-cultured human hepatocytes. Toxicol In Vitro 2016; 34: 179-186
[195] Lu W, Cheng F, Jiang J, Zhang C, Deng X, Xu Z, et al. FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach. Sci Rep 2015; 5: 8114
[196] Burbank MG, Burban A, Sharanek A, Weaver RJ, Guguen-Guillouzo C, Guillouzo A. Early alterations of bile canaliculi dynamics and the Rho kinase/myosin light chain kinase pathway are characteristics of drug-induced intrahepatic cholestasis. Drug Metab Dispos 2016; 44: 1780-1793
[197] Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology 2006; 43: S54-S62
[198] Robinson MW, Harmon C, O'Farrelly C. Liver immunology and its role in inflammation and homeostasis. Cell Mol Immunol 2016; 13: 267-276
[199] Papay JI, Clines D, Rafi R, Yuen N, Britt SD, Walsh JS, et al. Drug-induced liver injury following positive drug rechallenge. Regul Toxicol Pharmacol 2009; 54: 84-90
[200] Ju C, Reilly T. Role of immune reactions in drug-induced liver injury (DILI). Drug Metab Rev 2012; 44: 107-115
[201] Clare KE, Miller MH, Dillon JF. Genetic factors influencing drug-induced liver injury: do they have a role in prevention and diagnosis?. Curr Hepatol Rep 2017; 16: 258-264
[202] Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41: 816-819
[203] Monshi MM, Faulkner L, Gibson A, Jenkins RE, Farrell J, Earnshaw CJ, et al. Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 2013; 57: 727-739
[204] Nicoletti P, Aithal GP, Chamberlain TC, Coulthard S, Alshabeeb M, Grove JI, et al. Drug-induced liver injury due to flucloxacillin: relevance of multiple human leukocyte antigen alleles. Clin Pharmacol Ther 2019; 106: 245-253
[205] Hautekeete ML, Horsmans Y, Van Waeyenberge C, Demanet C, Henrion J, Verbist L, et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 1999; 117: 1181-1186
[206] Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011; 141: 338-347
[207] Stephens C, Lopez-Nevot MA, Ruiz-Cabello F, Ulzurrun E, Soriano G, Romero-Gomez M, et al. HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One 2013; 8: e68111
[208] O'Donohue J, Oien KA, Donaldson P, Underhill J, Clare M, MacSween RN, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000; 47: 717-720
[209] Donaldson PT, Daly AK, Henderson J, Graham J, Pirmohamed M, Bernal W, et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol 2010; 53: 1049-1053
[210] Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008; 8: 186-195
[211] Parham LR, Briley LP, Li L, Shen J, Newcombe PJ, King KS, et al. Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01. Pharmacogenomics J 2016; 16: 180-185
[212] Pollmacher T, Hinze-Selch D, Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 1996; 16: 403-409
[213] Kato R, Uetrecht J. Supernatant from hepatocyte cultures with drugs that cause idiosyncratic liver injury activates macrophage inflammasomes. Chem Res Toxicol 2017; 30: 1327-1332
[214] Jee A, Sernoskie SC, Uetrecht J. Idiosyncratic drug-induced liver injury: mechanistic and clinical challenges. Int J Mol Sci 2021; 22: 2954
[215] Kouwenhoven M, Ozenci V, Teleshova N, Hussein Y, Huang YM, Eusebio A, et al. Enzyme-linked immunospot assays provide a sensitive tool for detection of cytokine secretion by monocytes. Clin Diagn Lab Immunol 2001; 8: 1248-1257
[216] Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004; 59: 809-820
[217] Rive CM, Bourke J, Phillips EJ. Testing for drug hypersensitivity syndromes. Clin Biochem Rev 2013; 34: 15-38
[218] Whritenour J, Ko M, Zong Q, Wang J, Tartaro K, Schneider P, et al. Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response. J Immunotoxicol 2017; 14: 31-38
[219] Usui T, Faulkner L, Farrell J, French NS, Alfirevic A, Pirmohamed M, et al. Application of in vitro T cell assay using human leukocyte antigen-typed healthy donors for the assessment of drug immunogenicity. Chem Res Toxicol 2018; 31: 165-167
[220] Oda S, Matsuo K, Nakajima A, Yokoi T. A novel cell-based assay for the evaluation of immune- and inflammatory-related gene expression as biomarkers for the risk assessment of drug-induced liver injury. Toxicol Lett 2016; 241: 60-70
[221] Ogese MO, Faulkner L, Jenkins RE, French NS, Copple IM, Antoine DJ, et al. Characterization of drug-specific signaling between primary human hepatocytes and immune cells. Toxicol Sci 2017; 158: 76-89
[222] Cosgrove BD, King BM, Hasan MA, Alexopoulos LG, Farazi PA, Hendriks BS, et al. Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol Appl Pharmacol 2009; 237: 317-330
[223] Zou W, Roth RA, Younis HS, Burgoon LD, Ganey PE. Oxidative stress is important in the pathogenesis of liver injury induced by sulindac and lipopolysaccharide cotreatment. Toxicology 2010; 272: 32-38
[224] Fredriksson L, Herpers B, Benedetti G, Matadin Q, Puigvert JC, de Bont H, et al. Diclofenac inhibits tumor necrosis factor-alpha-induced nuclear factor-kappaB activation causing synergistic hepatocyte apoptosis. Hepatology 2011; 53: 2027-2041
[225] Beggs KM, Maiuri AR, Fullerton AM, Poulsen KL, Breier AB, Ganey PE, et al. Trovafloxacin-induced replication stress sensitizes HepG2 cells to tumor necrosis factor-alpha-induced cytotoxicity mediated by extracellular signal-regulated kinase and ataxia telangiectasia and Rad3-related. Toxicology 2015; 331: 35-46
[226] Oda S, Uchida Y, Aleo MD, Koza-Taylor PH, Matsui Y, Hizue M, et al. An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol 2021; 95: 149-168
[227] LeCluyse EL, Witek RP, Andersen ME, Powers MJ. Organotypic liver culture models: meeting current challenges in toxicity testing. Crit Rev Toxicol 2012; 42: 501-548
[228] Persson M. High content screening for prediction of human drug-induced liver injury. In: Chen M, Will Y, editors. Drug-induced liver toxicity. New York: Humana; 2018. p. 331-343
[229] Donato M, Tolosa L. High-content screening for the detection of drug-induced oxidative stress in liver cells. Antioxidants (Basel) 2021; 10: 106
[230] Trask OJ, Jr., Moore A, LeCluyse EL. A micropatterned hepatocyte coculture model for assessment of liver toxicity using high-content imaging analysis. Assay Drug Dev Technol 2014; 12: 16-27
[231] Tolosa L, Gomez-Lechon MJ, Donato MT. High-content screening technology for studying drug-induced hepatotoxicity in cell models. Arch Toxicol 2015; 89: 1007-1022
[232] Bougen-Zhukov N, Loh SY, Lee HK, Loo LH. Large-scale image-based screening and profiling of cellular phenotypes. Cytometry A 2017; 91: 115-125
[233] Meijering E, Dzyubachyk O, Smal I. Methods for cell and particle tracking. Methods Enzymol 2012; 504: 183-200
[234] Kozak K, Rinn B, Leven O, Emmenlauer M. Strategies and solutions to maintain and retain data from high content imaging, analysis, and screening assays. Methods Mol Biol 2018; 1683: 131-148
[235] Persson M, Loye AF, Mow T, Hornberg JJ. A high content screening assay to predict human drug-induced liver injury during drug discovery. J Pharmacol Toxicol Methods 2013; 68: 302-313
[236] Lu J, Einhorn S, Venkatarangan L, Miller M, Mann DA, Watkins PB, et al. Morphological and functional characterization and assessment of iPSC-derived hepatocytes for in vitro toxicity testing. Toxicol Sci 2015; 147: 39-54
[237] Pradip A, Steel D, Jacobsson S, Holmgren G, Ingelman-Sundberg M, Sartipy P, et al. High content analysis of human pluripotent stem cell derived hepatocytes reveals drug induced steatosis and phospholipidosis. Stem Cells Int 2016; 2016: 2475631
[238] Ware BR, Berger DR, Khetani SR. Prediction of drug-induced liver injury in micropatterned co-cultures containing iPSC-derived human hepatocytes. Toxicol Sci 2015; 145: 252-262
[239] Hiemstra S, Ramaiahgari SC, Wink S, Callegaro G, Coonen M, Meerman J, et al. High-throughput confocal imaging of differentiated 3D liver-like spheroid cellular stress response reporters for identification of drug-induced liver injury liability. Arch Toxicol 2019; 93: 2895-2911
[240] Cha HJ, Ko MJ, Ahn SM, Ahn JI, Shin HJ, Jeong HS, et al. Identification of classifier genes for hepatotoxicity prediction in non steroidal anti inflammatory drugs. Mol Cell Toxicol 2010; 6: 247-253
[241] Ware BR, McVay M, Sunada WY, Khetani SR. Exploring chronic drug effects on microengineered human liver cultures using global gene expression profiling. Toxicol Sci 2017; 157: 387-398
[242] Robles-Diaz M, Medina-Caliz I, Stephens C, Andrade RJ, Lucena MI. Biomarkers in DILI: one more step forward. Front Pharmacol 2016; 7: 267
[243] Russo MW, Steuerwald N, Norton HJ, Anderson WE, Foureau D, Chalasani N, et al. Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance. Liver Int 2017; 37: 757-764
[244] Koberle V, Pleli T, Schmithals C, Augusto Alonso E, Haupenthal J, Bonig H, et al. Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers. PLoS One 2013; 8: e75184
[245] Sato K, Meng F, Glaser S, Alpini G. Exosomes in liver pathology. J Hepatol 2016; 65: 213-221
[246] Momen-Heravi F, Saha B, Kodys K, Catalano D, Satishchandran A, Szabo G. Increased number of circulating exosomes and their microRNA cargos are potential novel biomarkers in alcoholic hepatitis. J Transl Med 2015; 13: 261
[247] Holman NS, Mosedale M, Wolf KK, LeCluyse EL, Watkins PB. Subtoxic alterations in hepatocyte-derived exosomes: an early step in drug-induced liver injury?. Toxicol Sci 2016; 151: 365-375
[248] Ruiz-Aracama A, Peijnenburg A, Kleinjans J, Jennen D, van Delft J, Hellfrisch C, et al. An untargeted multi-technique metabolomics approach to studying intracellular metabolites of HepG2 cells exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. BMC Genomics 2011; 12: 251
[249] Krajnc E, Visentin M, Gai Z, Stieger B, Samodelov SL, Hausler S, et al. Untargeted metabolomics reveals anaerobic glycolysis as a novel target of the hepatotoxic antidepressant nefazodone. J Pharmacol Exp Ther 2020; 375: 239
[250] Shah F, Leung L, Barton HA, Will Y, Rodrigues AD, Greene N, et al. Setting clinical exposure levels of concern for drug-induced liver injury (DILI) using mechanistic in vitro assays. Toxicol Sci 2015; 147: 500-514
[251] Aleo MD, Luo Y, Swiss R, Bonin PD, Potter DM, Will Y. Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology 2014; 60: 1015-1022
[252] Aleo MD, Shah F, Allen S, Barton HA, Costales C, Lazzaro S, et al. Moving beyond binary predictions of human drug-induced liver injury (DILI) toward contrasting relative risk potential. Chem Res Toxicol 2020; 33: 223-238
[253] Nevzorova YA, Boyer-Diaz Z, Cubero FJ, Gracia-Sancho J. Animal models for liver disease-a practical approach for translational research. J Hepatol 2020; 73: 423-440
[254] Morgan SJ, Elangbam CS. Animal models of disease for future toxicity predictions. In: Will Y, McDuffie JE, Olaharski AJ, Jeffy BD, editors. Drug discovery toxicology: from target assessment to translational biomarkers. Chichester: John Wiley & Sons; 2016. p. 261-297
[255] Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000; 32: 56-67
[256] Ballet F. Preventing drug-induced liver injury: how useful are animal models?. Dig Dis 2015; 33: 477-485
[257] Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol 2020; 18: e3000410
[258] Lutkewitte AJ, Schweitzer GG, Kennon-McGill S, Clemens MM, James LP, Jaeschke H, et al. Lipin deactivation after acetaminophen overdose causes phosphatidic acid accumulation in liver and plasma in mice and humans and enhances liver regeneration. Food Chem Toxicol 2018; 115: 273-283
[259] Ramachandran A, Jaeschke H. Mechanisms of acetaminophen hepatotoxicity and their translation to the human pathophysiology. J Clin Transl Res 2017; 3: 157-169
[260] James LP, Chiew A, Abdel-Rahman SM, Letzig L, Graudins A, Day P, et al. Acetaminophen protein adduct formation following low-dose acetaminophen exposure: comparison of immediate-release vs. extended-release formulations. Eur J Clin Pharmacol 2013; 69: 851-857
[261] Thrall KD, Vucelick ME, Gies RA, Zangar RC, Weitz KK, Poet TS, et al. Comparative metabolism of carbon tetrachloride in rats, mice, and hamsters using gas uptake and PBPK modeling. J Toxicol Environ Health A 2000; 60: 531-548
[262] Metushi IG, Nakagawa T, Uetrecht J. Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: humans are more like mice than rats. Chem Res Toxicol 2012; 25: 2567-2576
[263] Korolczuk A, Caban K, Amarowicz M, Czechowska G, Irla-Miduch J. Oxidative stress and liver morphology in experimental cyclosporine A-induced hepatotoxicity. Biomed Res Int 2016; 2016: 5823271
[264] Hagar HH. The protective effect of taurine against cyclosporine A-induced oxidative stress and hepatotoxicity in rats. Toxicol Lett 2004; 151: 335-343
[265] Abdel-Dayem MA, Elmarakby AA, Abdel-Aziz AA, Pye C, Said SA, El-Mowafy AM. Valproate-induced liver injury: modulation by the omega-3 fatty acid DHA proposes a novel anticonvulsant regimen. Drugs R D 2014; 14: 85-94
[266] Sokmen BB, Tunali S, Yanardag R. Effects of vitamin U (S-methyl methionine sulphonium chloride) on valproic acid induced liver injury in rats. Food Chem Toxicol 2012; 50: 3562-3566
[267] Higuchi S, Yano A, Takai S, Tsuneyama K, Fukami T, Nakajima M, et al. Metabolic activation and inflammation reactions involved in carbamazepine-induced liver injury. Toxicol Sci 2012; 130: 4-16
[268] Pan Y, Cao M, You D, Qin G, Liu Z. Research progress on the animal models of drug-induced liver injury: current status and further perspectives. Biomed Res Int 2019; 2019: 1283824
[269] McGill MR, Williams CD, Xie Y, Ramachandran A, Jaeschke H. Acetaminophen-induced liver injury in rats and mice: comparison of protein adducts, mitochondrial dysfunction, and oxidative stress in the mechanism of toxicity. Toxicol Appl Pharmacol 2012; 264: 387-394
[270] Jaeschke H, Xie Y, McGill MR. Acetaminophen-induced liver injury: from animal models to humans. J Clin Transl Hepatol 2014; 2: 153-161
[271] Hall PD, Plummer JL, Ilsley AH, Cousins MJ. Hepatic fibrosis and cirrhosis after chronic administration of alcohol and "low-dose" carbon tetrachloride vapor in the rat. Hepatology 1991; 13: 815-819
[272] Tsuchida T, Lee YA, Fujiwara N, Ybanez M, Allen B, Martins S, et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J Hepatol 2018; 69: 385-395
[273] Chen X, Xu J, Zhang C, Yu T, Wang H, Zhao M, et al. The protective effects of ursodeoxycholic acid on isoniazid plus rifampicin induced liver injury in mice. Eur J Pharmacol 2011; 659: 53-60
[274] Metushi IG, Cai P, Dervovic D, Liu F, Lobach A, Nakagawa T, et al. Development of a novel mouse model of amodiaquine-induced liver injury with a delayed onset. J Immunotoxicol 2015; 12: 247-260
[275] Laifenfeld D, Qiu L, Swiss R, Park J, Macoritto M, Will Y, et al. Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury. Toxicol Sci 2014; 137: 234-248
[276] Mattes W, Davis K, Fabian E, Greenhaw J, Herold M, Looser R, et al. Detection of hepatotoxicity potential with metabolite profiling (metabolomics) of rat plasma. Toxicol Lett 2014; 230: 467-478
[277] Eun JW, Bae HJ, Shen Q, Park SJ, Kim HS, Shin WC, et al. Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model. J Appl Toxicol 2015; 35: 152-164
[278] Nolan JP. The role of intestinal endotoxin in liver injury: a long and evolving history. Hepatology 2010; 52: 1829-1835
[279] Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140: 805-820
[280] Buchweitz JP, Ganey PE, Bursian SJ, Roth RA. Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy?. J Pharmacol Exp Ther 2002; 300: 460-467
[281] Shaw PJ, Hopfensperger MJ, Ganey PE, Roth RA. Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha. Toxicol Sci 2007; 100: 259-266
[282] Lu J, Jones AD, Harkema JR, Roth RA, Ganey PE. Amiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats: role of tumor necrosis factor-alpha. Toxicol Sci 2012; 125: 126-133
[283] Deng X, Stachlewitz RF, Liguori MJ, Blomme EA, Waring JF, Luyendyk JP, et al. Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation. J Pharmacol Exp Ther 2006; 319: 1191-1199
[284] Waring JF, Liguori MJ, Luyendyk JP, Maddox JF, Ganey PE, Stachlewitz RF, et al. Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J Pharmacol Exp Ther 2006; 316: 1080-1087
[285] Zou W, Devi SS, Sparkenbaugh E, Younis HS, Roth RA, Ganey PE. Hepatotoxic interaction of sulindac with lipopolysaccharide: role of the hemostatic system. Toxicol Sci 2009; 108: 184-193
[286] Luyendyk JP, Maddox JF, Cosma GN, Ganey PE, Cockerell GL, Roth RA. Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J Pharmacol Exp Ther 2003; 307: 9-16
[287] Heidari R, Ahmadi F, Rahimi HR, Azarpira N, Hosseinzadeh M, Najibi A, et al. Exacerbated liver injury of antithyroid drugs in endotoxin-treated mice. Drug Chem Toxicol 2019; 42: 615-623
[288] Tukov FF, Luyendyk JP, Ganey PE, Roth RA. The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury. Toxicol Sci 2007; 100: 267-280
[289] Cueto-Sanchez A, Niu H, Del Campo-Herrera E, Robles-Diaz M, Sanabria-Cabrera J, Ortega-Alonso A, et al. Lymphocyte profile and immune checkpoint expression in drug-induced liver injury: an immunophenotyping study. Clin Pharmacol Ther 2021. Available from: https://doi.org/10.1002/cpt.2423
[290] Metushi IG, Hayes MA, Uetrecht J. Treatment of PD-1-/- mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients. Hepatology 2015; 61: 1332-1342
[291] Chakraborty M, Fullerton AM, Semple K, Chea LS, Proctor WR, Bourdi M, et al. Drug-induced allergic hepatitis develops in mice when myeloid-derived suppressor cells are depleted prior to halothane treatment. Hepatology 2015; 62: 546-557
[292] Mak A, Uetrecht J. The combination of anti-CTLA-4 and PD1-/- mice unmasks the potential of isoniazid and nevirapine to cause liver injury. Chem Res Toxicol 2015; 28: 2287-2291
[293] Mak A, Kato R, Weston K, Hayes A, Uetrecht J. Editor's highlight: an impaired immune tolerance animal model distinguishes the potential of troglitazone/pioglitazone and tolcapone/entacapone to cause IDILI. Toxicol Sci 2018; 161: 412-420
[294] Ong MM, Latchoumycandane C, Boelsterli UA. Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol Sci 2007; 97: 205-213
[295] Kashimshetty R, Desai VG, Kale VM, Lee T, Moland CL, Branham WS, et al. Underlying mitochondrial dysfunction triggers flutamide-induced oxidative liver injury in a mouse model of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 2009; 238: 150-159
[296] Hsiao CJ, Younis H, Boelsterli UA. Trovafloxacin, a fluoroquinolone antibiotic with hepatotoxic potential, causes mitochondrial peroxynitrite stress in a mouse model of underlying mitochondrial dysfunction. Chem Biol Interact 2010; 188: 204-213
[297] Morita M, Akai S, Hosomi H, Tsuneyama K, Nakajima M, Yokoi T. Drug-induced hepatotoxicity test using gamma-glutamylcysteine synthetase knockdown rat. Toxicol Lett 2009; 189: 159-165
[298] Akai S, Hosomi H, Minami K, Tsuneyama K, Katoh M, Nakajima M, et al. Knock down of gamma-glutamylcysteine synthetase in rat causes acetaminophen-induced hepatotoxicity. J Biol Chem 2007; 282: 23996-24003
[299] Iida A, Sasaki E, Yano A, Tsuneyama K, Fukami T, Nakajima M, et al. Carbamazepine-induced liver injury requires CYP3A-mediated metabolism and glutathione depletion in rats. Drug Metab Dispos 2015; 43: 958-968
[300] Forootan SS, Mutter FE, Kipar A, Iwawaki T, Francis B, Goldring CE, et al. Real-time in vivo imaging reveals localised Nrf2 stress responses associated with direct and metabolism-dependent drug toxicity. Sci Rep 2017; 7: 16084
[301] Dugan CM, MacDonald AE, Roth RA, Ganey PE. A mouse model of severe halothane hepatitis based on human risk factors. J Pharmacol Exp Ther 2010; 333: 364-372
[302] You Q, Cheng L, Reilly TP, Wegmann D, Ju C. Role of neutrophils in a mouse model of halothane-induced liver injury. Hepatology 2006; 44: 1421-1431
[303] Harrill AH, Watkins PB, Su S, Ross PK, Harbourt DE, Stylianou IM, et al. Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res 2009; 19: 1507-1515
[304] Kakuni M, Morita M, Matsuo K, Katoh Y, Nakajima M, Tateno C, et al. Chimeric mice with a humanized liver as an animal model of troglitazone-induced liver injury. Toxicol Lett 2012; 214: 9-18
[305] Ekdahl A, Weidolf L, Baginski M, Morikawa Y, Thompson RA, Wilson ID. The metabolic fate of fenclozic acid in chimeric mice with a humanized liver. Arch Toxicol 2018; 92: 2819-2828
[306] Yamazaki H, Suemizu H, Igaya S, Shimizu M, Shibata N, Nakamura M, et al. In vivo formation of a glutathione conjugate derived from thalidomide in humanized uPA-NOG mice. Chem Res Toxicol 2011; 24: 287-289
[307] Xu D, Wu M, Nishimura S, Nishimura T, Michie SA, Zheng M, et al. Chimeric TK-NOG mice: a predictive model for cholestatic human liver toxicity. J Pharmacol Exp Ther 2015; 352: 274-280
[308] Bility MT, Nio K, Li F, McGivern DR, Lemon SM, Feeney ER, et al. Chronic hepatitis C infection-induced liver fibrogenesis is associated with M2 macrophage activation. Sci Rep 2016; 6: 39520
[309] Gutti TL, Knibbe JS, Makarov E, Zhang J, Yannam GR, Gorantla S, et al. Human hepatocytes and hematolymphoid dual reconstitution in treosulfan-conditioned uPA-NOG mice. Am J Pathol 2014; 184: 101-109
[310] Wilson EM, Bial J, Tarlow B, Bial G, Jensen B, Greiner DL, et al. Extensive double humanization of both liver and hematopoiesis in FRGN mice. Stem Cell Res 2014; 13: 404-412
[311] Song B, Aoki S, Liu C, Susukida T, Ito K. An animal model of abacavir-induced HLA-mediated liver injury. Toxicol Sci 2018; 162: 713-723
[312] Pan RY, Chu MT, Wang CW, Lee YS, Lemonnier F, Michels AW, et al. Identification of drug-specific public TCR driving severe cutaneous adverse reactions. Nat Commun 2019; 10: 3569
[313] Susukida T, Aoki S, Shirayanagi T, Yamada Y, Kuwahara S, Ito K. HLA transgenic mice: application in reproducing idiosyncratic drug toxicity. Drug Metab Rev 2020; 52: 540-567
[314] Jiang W, Dai T, Xie S, Ding L, Huang L, Dai R. Roles of diclofenac and its metabolites in immune activation associated with acute hepatotoxicity in TgCYP3A4/hPXR-humanized mice. Int Immunopharmacol 2020; 86: 106723
[315] Li F, Lu J, Cheng J, Wang L, Matsubara T, Csanaky IL, et al. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat Med 2013; 19: 418-420
[316] Moriguchi T, Motohashi H, Hosoya T, Nakajima O, Takahashi S, Ohsako S, et al. Distinct response to dioxin in an arylhydrocarbon receptor (AHR)-humanized mouse. Proc Natl Acad Sci U S A 2003; 100: 5652-5657
[317] Scheer N, Kapelyukh Y, Rode A, Oswald S, Busch D, McLaughlin LA, et al. Defining human pathways of drug metabolism in vivo through the development of a multiple humanized mouse model. Drug Metab Dispos 2015; 43: 1679-1690
[318] Cho T, Kok LY, Uetrecht J. Testing possible risk factors for idiosyncratic drug-induced liver injury using an amodiaquine mouse model and co-treatment with 1-methyl-D-tryptophan or acetaminophen. ACS Omega 2021; 6: 4656-4662
[319] Fujimoto K, Kumagai K, Ito K, Arakawa S, Ando Y, Oda S, et al. Sensitivity of liver injury in heterozygous Sod2 knockout mice treated with troglitazone or acetaminophen. Toxicol Pathol 2009; 37: 193-200
[320] Lucena MI, Garcia-Martin E, Andrade RJ, Martinez C, Stephens C, Ruiz JD, et al. Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. Hepatology 2010; 52: 303-312
[321] Huang YS, Su WJ, Huang YH, Chen CY, Chang FY, Lin HC, et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 2007; 47: 128-134
[322] Yokoi T, Oda S. Models of idiosyncratic drug-induced liver injury. Annu Rev Pharmacol Toxicol 2021; 61: 247-268
[323] Griffith OW. Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J Biol Chem 1982; 257: 13704-13712
[324] Sasaki E, Iida A, Oda S, Tsuneyama K, Fukami T, Nakajima M, et al. Pathogenetic analyses of carbamazepine-induced liver injury in F344 rats focused on immune- and inflammation-related factors. Exp Toxicol Pathol 2016; 68: 27-38
[325] Cousins MJ, Plummer JL, Hall PD. Risk factors for halothane hepatitis. Aust N Z J Surg 1989; 59: 5-14
[326] Inman WH, Mushin WW. Jaundice after repeated exposure to halothane: a further analysis of reports to the Committee on Safety of Medicines. Br Med J 1978; 2: 1455-1456
[327] Church RJ, Wu H, Mosedale M, Sumner SJ, Pathmasiri W, Kurtz CL, et al. A systems biology approach utilizing a mouse diversity panel identifies genetic differences influencing isoniazid-induced microvesicular steatosis. Toxicol Sci 2014; 140: 481-492
[328] Shaw PJ, Ganey PE, Roth RA. Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol Sci 2010; 118: 7-18
[329] Scheer N, Wilson ID. A comparison between genetically humanized and chimeric liver humanized mouse models for studies in drug metabolism and toxicity. Drug Discov Today 2016; 21: 250-263
[330] Strom SC, Davila J, Grompe M. Chimeric mice with humanized liver: tools for the study of drug metabolism, excretion, and toxicity. Methods Mol Biol 2010; 640: 491-509
[331] Jin M, Yi X, Liao W, Chen Q, Yang W, Li Y, et al. Advancements in stem cell-derived hepatocyte-like cell models for hepatotoxicity testing. Stem Cell Res Ther 2021; 12: 84
[332] Sanoh S, Ohta S. Chimeric mice transplanted with human hepatocytes as a model for prediction of human drug metabolism and pharmacokinetics. Biopharm Drug Dispos 2014; 35: 71-86
[333] Yuan L, Liu X, Zhang L, Zhang Y, Chen Y, Li X, et al. Optimized HepaRG is a suitable cell source to generate the human liver chimeric mouse model for the chronic hepatitis B virus infection. Emerg Microbes Infect 2018; 7: 144
[334] Foster JR, Lund G, Sapelnikova S, Tyrrell DL, Kneteman NM. Chimeric rodents with humanized liver: bridging the preclinical/clinical trial gap in ADME/toxicity studies. Xenobiotica 2014; 44: 109-122
[335] Dandri M, Burda MR, Torok E, Pollok JM, Iwanska A, Sommer G, et al. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 2001; 33: 981-988
[336] Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927-933
[337] Suemizu H, Hasegawa M, Kawai K, Taniguchi K, Monnai M, Wakui M, et al. Establishment of a humanized model of liver using NOD/Shi-scid IL2Rgnull mice. Biochem Biophys Res Commun 2008; 377: 248-252
[338] Azuma H, Paulk N, Ranade A, Dorrell C, Al-Dhalimy M, Ellis E, et al. Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol 2007; 25: 903-910
[339] Hasegawa M, Kawai K, Mitsui T, Taniguchi K, Monnai M, Wakui M, et al. The reconstituted ‘humanized liver’ in TK-NOG mice is mature and functional. Biochem Biophys Res Commun 2011; 405: 405-410
[340] Zhang RR, Zheng YW, Li B, Tsuchida T, Ueno Y, Nie YZ, et al. Human hepatic stem cells transplanted into a fulminant hepatic failure Alb-TRECK/SCID mouse model exhibit liver reconstitution and drug metabolism capabilities. Stem Cell Res Ther 2015; 6: 49
[341] Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004; 165: 901-912
[342] Tateno C, Kawase Y, Tobita Y, Hamamura S, Ohshita H, Yokomichi H, et al. Generation of novel chimeric mice with humanized livers by using hemizygous cDNA-uPA/SCID mice. PLoS One 2015; 10: e0142145
[343] Miyamoto M, Kosugi Y, Iwasaki S, Chisaki I, Nakagawa S, Amano N, et al. Characterization of plasma protein binding in two mouse models of humanized liver, PXB mouse and humanized TK-NOG mouse. Xenobiotica 2021; 51: 51-60
[344] Yamazaki H, Kuribayashi S, Inoue T, Honda T, Tateno C, Oofusa K, et al. Zone analysis by two-dimensional electrophoresis with accelerator mass spectrometry of in vivo protein bindings of idiosyncratic hepatotoxicants troglitazone and flutamide bioactivated in chimeric mice with humanized liver. Toxicol Res 2015; 4: 106-111
[345] Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 2013; 499: 481-484
[346] Xu D, Nishimura T, Nishimura S, Zhang H, Zheng M, Guo YY, et al. Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing. PLoS Med 2014; 11: e1001628
[347] Xu D, Michie SA, Zheng M, Takeda S, Wu M, Peltz G. Humanized thymidine kinase-NOG mice can be used to identify drugs that cause animal-specific hepatotoxicity: a case study with furosemide. J Pharmacol Exp Ther 2015; 354: 73-78
[348] Barzi M, Pankowicz FP, Zorman B, Liu X, Legras X, Yang D, et al. A novel humanized mouse lacking murine P450 oxidoreductase for studying human drug metabolism. Nat Commun 2017; 8: 39
[349] Zschaler J, Schlorke D, Arnhold J. Differences in innate immune response between man and mouse. Crit Rev Immunol 2014; 34: 433-454
[350] Washburn ML, Bility MT, Zhang L, Kovalev GI, Buntzman A, Frelinger JA, et al. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology 2011; 140: 1334-1344
[351] Kim J, Ryu B, Kim U, Kim C-H, Hur GH, Kim CY, et al. Improved human hematopoietic reconstitution in HepaRG co-transplanted humanized NSG mice. BMB Reports 2020; 53: 466-471
[352] Dagur RS, Wang W, Makarov E, Sun Y, Poluektova LY. Establishment of the dual humanized TK-NOG mouse model for HIV-associated liver pathogenesis. J Vis Exp 2019; 151: 10.3791/58645
[353] Matsunaga T, Cabilly-Horesh O, Terz D, Lee A, Christian L, Ohno S, et al. Use of transgenic mice with human MHC class 1 gene (HLA-A2). In: Klaus GGB, Editor Microenvironments in the lymphoid system. Boston: Springer; 1985. p. 341-347
[354] Yuksel M, Wang Y, Tai N, Peng J, Guo J, Beland K, et al. A novel "humanized mouse" model for autoimmune hepatitis and the association of gut microbiota with liver inflammation. Hepatology 2015; 62: 1536-1550
[355] Susukida T, Aoki S, Kogo K, Fujimori S, Song B, Liu C, et al. Evaluation of immune-mediated idiosyncratic drug toxicity using chimeric HLA transgenic mice. Arch Toxicol 2018; 92: 1177-1188
[356] Cardone M, Garcia K, Tilahun ME, Boyd LF, Gebreyohannes S, Yano M, et al. A transgenic mouse model for HLA-B*57:01-linked abacavir drug tolerance and reactivity. J Clin Invest 2018; 128: 2819-2832
[357] Lundgren H, Martinsson K, Cederbrant K, Jirholt J, Mucs D, Madeyski-Bengtson K, et al. . PLoS One 2017; 12: e0184744
[358] Pavlos R, Deshpande P, Chopra A, Leary S, Strautins K, Nolan D, et al. New genetic predictors for abacavir tolerance in HLA-B*57:01 positive individuals. Hum Immunol 2020; 81: 300-304
[359] Cirulli ET, Nicoletti P, Abramson K, Andrade RJ, Bjornsson ES, Chalasani N, et al. A missense variant in PTPN22 is a risk factor for drug-induced liver injury. Gastroenterology 2019; 156: 1707-17016 e2
[360] Wang J, Bwayi M, Gee RRF, Chen T. PXR-mediated idiosyncratic drug-induced liver injury: mechanistic insights and targeting approaches. Expert Opin Drug Metab Toxicol 2020; 16: 711-722
[361] Bissig KD, Han W, Barzi M, Kovalchuk N, Ding L, Fan X, et al. P450-humanized and human liver chimeric mouse models for studying xenobiotic metabolism and toxicity. Drug Metab Dispos 2018; 46: 1734-1744
[362] Li X, Chen Y, Song X, Zhang Y, Li H, Zhao Y. The development and application of in silico models for drug induced liver injury. RSC Advances 2018; 8: 8101-8111
[363] Cheng A, Dixon SL. In silico models for the prediction of dose-dependent human hepatotoxicity. J Comput Aided Mol Des 2003; 17: 811-823
[364] Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ. Developing structure-activity relationships for the prediction of hepatotoxicity. Chem Res Toxicol 2010; 23: 1215-1222
[365] Hewitt M, Przybylak K. In silico models for hepatotoxicity. Methods Mol Biol 2016; 1425: 201-236
[366] Woodhead JL, Watkins PB, Howell BA, Siler SQ, Shoda LKM. The role of quantitative systems pharmacology modeling in the prediction and explanation of idiosyncratic drug-induced liver injury. Drug Metab Pharmacokinet 2017; 32: 40-45
[367] Marchant CA, Fisk L, Note RR, Patel ML, Suarez D. An expert system approach to the assessment of hepatotoxic potential. Chem Biodivers 2009; 6: 2107-2114
[368] Chen M, Bisgin H, Tong L, Hong H, Fang H, Borlak J, et al. Toward predictive models for drug-induced liver injury in humans: are we there yet?. Biomark Med 2014; 8: 201-213
[369] Williams DP, Lazic SE, Foster AJ, Semenova E, Morgan P. Predicting drug-induced liver injury with bayesian machine learning. Chem Res Toxicol 2020; 33: 239-248
[370] Li T, Tong W, Roberts R, Liu Z, Thakkar S. Deep learning on high-throughput transcriptomics to predict drug-induced liver injury. Front Bioeng Biotechnol 2020; 8: 562677
[371] Hong H, Thakkar S, Chen M, Tong W. Development of decision forest models for prediction of drug-induced liver injury in humans using a large set of FDA-approved drugs. Sci Rep 2017; 7: 17311
[372] Schoning V, Krahenbuhl S, Drewe J. The hepatotoxic potential of protein kinase inhibitors predicted with Random Forest and Artificial Neural Networks. Toxicol Lett 2018; 299: 145-148
[373] Przybylak KR, Cronin MT. In silico models for drug-induced liver injury-current status. Expert Opin Drug Metab Toxicol 2012; 8: 201-217
[374] Zhu XW, Sedykh A, Liu SS. Hybrid in silico models for drug-induced liver injury using chemical descriptors and in vitro cell-imaging information. J Appl Toxicol 2014; 34: 281-288
[375] Liu R, Yu X, Wallqvist A. Data-driven identification of structural alerts for mitigating the risk of drug-induced human liver injuries. J Cheminform 2015; 7: 4
[376] Gonzalez-Jimenez A, Suzuki A, Chen M, Ashby K, Alvarez-Alvarez I, Andrade RJ, et al. Drug properties and host factors contribute to biochemical presentation of drug-induced liver injury: a prediction model from a machine learning approach. Arch Toxicol 2021; 95: 1793-1803
[377] Shoda LK, Woodhead JL, Siler SQ, Watkins PB, Howell BA. Linking physiology to toxicity using DILIsym®, a mechanistic mathematical model of drug-induced liver injury. Biopharm Drug Dispos 2014; 35: 33-49
[378] Howell BA, Yang Y, Kumar R, Woodhead JL, Harrill AH, Clewell HJ 3rd, et al. In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym: a mechanistic, mathematical model of DILI. J Pharmacokinet Pharmacodyn 2012; 39: 527-541
[379] Yang K, Woodhead JL, Watkins PB, Howell BA, Brouwer KL. Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity. Clin Pharmacol Ther 2014; 96: 589-598
[380] Longo DM, Yang Y, Watkins PB, Howell BA, Siler SQ. Elucidating differences in the hepatotoxic potential of tolcapone and entacapone with DILIsym(®), a mechanistic model of drug-induced liver injury. CPT Pharmacometrics Syst Pharmacol 2016; 5: 31-39
[381] Howell BA, Siler SQ, Watkins PB. Use of a systems model of drug-induced liver injury (DILIsym(®) to elucidate the mechanistic differences between acetaminophen and its less-toxic isomer, AMAP, in mice. Toxicol Lett 2014; 226: 163-172
[382] Yang Y, Nadanaciva S, Will Y, Woodhead JL, Howell BA, Watkins PB, et al. MITOsym®: a mechanistic, mathematical model of hepatocellular respiration and bioenergetics. Pharm Res 2015; 32: 1975-1992
[383] Woodhead JL, Brock WJ, Roth SE, Shoaf SE, Brouwer KL, Church R, et al. Application of a mechanistic model to evaluate putative mechanisms of tolvaptan drug-induced liver injury and identify patient susceptibility factors. Toxicol Sci 2017; 155: 61-74
[384] Woodhead JL, Yang K, Oldach D, MacLauchlin C, Fernandes P, Watkins PB, et al. Analyzing the mechanisms behind macrolide antibiotic-induced liver injury using quantitative systems toxicology modeling. Pharm Res 2019; 36: 48
[385] Longo DM, Woodhead JL, Walker P, Heredi-Szabo K, Mogyorosi K, Wolenski FS, et al. Quantitative systems toxicology analysis of in vitro mechanistic assays reveals importance of bile acid accumulation and mitochondrial dysfunction in TAK-875-induced liver injury. Toxicol Sci 2019; 167: 458-467
[386] Cruz-Monteagudo M, Cordeiro MN, Borges F. Computational chemistry approach for the early detection of drug-induced idiosyncratic liver toxicity. J Comput Chem 2008; 29: 533-549
[387] Thakkar S, Chen M, Fang H, Liu Z, Roberts R, Tong W. The Liver Toxicity Knowledge Base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury. Expert Rev Gastroenterol Hepatol 2018; 12: 31-38
[388] Judson R, Richard A, Dix D, Houck K, Elloumi F, Martin M, et al. ACToR-aggregated computational toxicology resource. Toxicol Appl Pharmacol 2008; 233: 7-13
[389] Igarashi Y, Nakatsu N, Yamashita T, Ono A, Ohno Y, Urushidani T, et al. Open TG-GATEs: a large-scale toxicogenomics database. Nucleic Acids Res 2015; 43: D921-D927
[390] Zhu XW, Li SJ. In silico prediction of drug-induced liver injury based on adverse drug reaction reports. Toxicol Sci 2017; 158: 391-400
[391] Stephens C, Robles-Diaz M, Medina-Caliz I, Garcia-Cortes M, Ortega-Alonso A, Sanabria-Cabrera J, et al. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. J Hepatol 2021; 75: 86-97
[392] Bessone F, Hernandez N, Lucena MI, Andrade RJ, Network ObotLD, Registry SD. The Latin American DILI registry experience: a successful ongoing collaborative strategic initiative. Int J Mol Sci 2016; 17: 313
[393] Devarbhavi H, Joseph T, Sunil Kumar N, Rathi C, Thomas V, Prasad Singh S, et al. The Indian network of drug-induced liver injury: etiology, clinical features, outcome and prognostic markers in 1288 patients. J Clin Exp Hepatol 2021; 11: 288-298
[394] Jain S, Norinder U, Escher SE, Zdrazil B. Combining in vivo data with in silico predictions for modeling hepatic steatosis by using stratified bagging and conformal prediction. Chem Res Toxicol 2021; 34: 656-668
[395] Sanz F, Carrio P, Lopez O, Capoferri L, Kooi DP, Vermeulen NP, et al. Integrative modeling strategies for predicting drug toxicities at the eTOX project. Mol Inform 2015; 34: 477-484
[396] Benesic A, Leitl A, Gerbes AL. Monocyte-derived hepatocyte-like cells for causality assessment of idiosyncratic drug-induced liver injury. Gut 2016; 65: 1555-1563
[397] Benesic A, Rotter I, Dragoi D, Weber S, Leitl A, Buchholtz ML, et al. Development and validation of a test to identify drugs that cause idiosyncratic drug-induced liver injury. Clin Gastroenterol Hepatol 2018; 16: 1488-14894 e5
[398] Dragoi D, Benesic A, Pichler G, Kulak NA, Bartsch HS, Gerbes AL. Proteomics analysis of monocyte-derived hepatocyte-like cells identifies integrin beta 3 as a specific biomarker for drug-induced liver injury by diclofenac. Front Pharmacol 2018; 9: 699
[399] Huang P, He Z, Ji S, Sun H, Xiang D, Liu C, et al. Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature 2011; 475: 386-389
[400] Sekiya S, Suzuki A. Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. Nature 2011; 475: 390-393
[401] Simeonov KP, Uppal H. Direct reprogramming of human fibroblasts to hepatocyte-like cells by synthetic modified mRNAs. PLoS One 2014; 9: e100134
[402] Huang P, Zhang L, Gao Y, He Z, Yao D, Wu Z, et al. Direct reprogramming of human fibroblasts to functional and expandable hepatocytes. Cell Stem Cell 2014; 14: 370-384
[403] Du Y, Wang J, Jia J, Song N, Xiang C, Xu J, et al. Human hepatocytes with drug metabolic function induced from fibroblasts by lineage reprogramming. Cell Stem Cell 2014; 14: 394-403
[404] Nakamori D, Akamine H, Takayama K, Sakurai F, Mizuguchi H. Direct conversion of human fibroblasts into hepatocyte-like cells by ATF5, PROX1, FOXA2, FOXA3, and HNF4A transduction. Sci Rep 2017; 7: 16675
[405] Ballester M, Bolonio M, Santamaria R, Castell JV, Ribes-Koninckx C, Bort R. Direct conversion of human fibroblast to hepatocytes using a single inducible polycistronic vector. Stem Cell Res Ther 2019; 10: 317
[406] Vallier L. Heps with pep: direct reprogramming into human hepatocytes. Cell Stem Cell 2014; 14: 267-269
[407] Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology 2015; 148: 1340-13452 e7
[408] Sanabria-Cabrera J, Medina-Caliz I, Stankeviciute S, Rodriguez-Nicolas A, Almarza-Torres M, Lucena MI, et al. Drug-induced liver injury associated with severe cutaneous hypersensitivity reactions: a complex entity in need of a multidisciplinary approach. Curr Pharm Des 2019; 25: 3855-3871
[409] Lin IC, Yang HC, Strong C, Yang CW, Cho YT, Chen KL, et al. Liver injury in patients with DRESS: A clinical study of 72 cases. J Am Acad Dermatol 2015; 72: 984-991
[410] Devarbhavi H, Raj S, Aradya VH, Rangegowda VT, Veeranna GP, Singh R, et al. Drug-induced liver injury associated with Stevens-Johnson syndrome/toxic epidermal necrolysis: patient characteristics, causes, and outcome in 36 cases. Hepatology 2016; 63: 993-999
[411] Ichai P, Laurent-Bellue A, Saliba F, Moreau D, Besch C, Francoz C, et al. Acute liver failure/injury related to drug reaction with eosinophilia and systemic symptoms: outcomes and prognostic factors. Transplantation 2017; 101: 1830-1837
[412] Walsh S, Diaz-Cano S, Higgins E, Morris-Jones R, Bashir S, Bernal W, et al. Drug reaction with eosinophilia and systemic symptoms: is cutaneous phenotype a prognostic marker for outcome? A review of clinicopathological features of 27 cases. Br J Dermatol 2013; 168: 391-401
[413] Illing PT, Purcell AW, McCluskey J. The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions. Immunogenetics 2017; 69: 617-630
[414] Sousa-Pinto B, Correia C, Gomes L, Gil-Mata S, Araujo L, Correia O, et al. HLA and delayed drug-induced hypersensitivity. Int Arch Allergy Immunol 2016; 170: 163-179
[415] Nicoletti P, Barrett S, McEvoy L, Daly AK, Aithal G, Lucena MI, et al. Shared genetic risk factors across carbamazepine-induced hypersensitivity reactions. Clin Pharmacol Ther 2019; 106: 1028-1036
[416] Sharma AM, Uetrecht J. Bioactivation of drugs in the skin: relationship to cutaneous adverse drug reactions. Drug Metab Rev 2014; 46: 1-18
[417] Yano A, Oda S, Fukami T, Nakajima M, Yokoi T. Development of a cell-based assay system considering drug metabolism and immune- and inflammatory-related factors for the risk assessment of drug-induced liver injury. Toxicol Lett 2014; 228: 13-24
[418] Hirashima R, Itoh T, Tukey RH, Fujiwara R. Prediction of drug-induced liver injury using keratinocytes. J Appl Toxicol 2017; 37: 863-872
[419] Wojtowicz AM, Oliveira S, Carlson MW, Zawadzka A, Rousseau CF, Baksh D. The importance of both fibroblasts and keratinocytes in a bilayered living cellular construct used in wound healing. Wound Repair Regen 2014; 22: 246-255
[420] Petrov PD, Fernandez-Murga ML, Lopez-Riera M, Gomez-Lechon MJ, Castell JV, Jover R. Predicting drug-induced cholestasis: preclinical models. Expert Opin Drug Metab Toxicol 2018; 14: 721-738
[421] Cheng Y, Chen S, Freeden C, Chen W, Zhang Y, Abraham P, et al. Bile salt homeostasis in normal and Bsep gene knockout rats with single and repeated doses of troglitazone. J Pharmacol Exp Ther 2017; 362: 385-394
[422] Lam P, Soroka CJ, Boyer JL. The bile salt export pump: clinical and experimental aspects of genetic and acquired cholestatic liver disease. Semin Liver Dis 2010; 30: 125-133
[423] Yuan L, Liu X, Zhang L, Li X, Zhang Y, Wu K, et al. A chimeric humanized mouse model by engrafting the human induced pluripotent stem cell-derived hepatocyte-like cell for the chronic hepatitis B virus infection. Front Microbiol 2018; 9: 908
[424] Hsu YC, Chen CT, Wei YH. Mitochondrial resetting and metabolic reprogramming in induced pluripotent stem cells and mitochondrial disease modeling. Biochim Biophys Acta 2016; 1860: 686-693
[425] Suhr ST, Chang EA, Tjong J, Alcasid N, Perkins GA, Goissis MD, et al. Mitochondrial rejuvenation after induced pluripotency. PLoS One 2010; 5: e14095
[426] Koido M, Kawakami E, Fukumura J, Noguchi Y, Ohori M, Nio Y, et al. Polygenic architecture informs potential vulnerability to drug-induced liver injury. Nat Med 2020; 26: 1541-1548
Similar articles: